Bringing New Delivery Methods to Treatments: Q&A with Richard Lowenthal

Key Takeaways

• neffy nasal spray approved March 2025, first epinephrine innovation in 35 years
• Needle‑free design reduces treatment hesitation, improving early anaphylaxis response
• Study shows 90% of users effectively treated with one neffy dose
• neffy tolerates up to 122 °F, frozen conditions, and lasts 2.5 years
• Schools can receive neffy free via neffyinSchools program, expanding access

Pulse Analysis

The approval of neffy underscores a growing trend in pharma: rethinking how life‑saving drugs reach patients. Traditional epinephrine auto‑injectors have dominated the market for decades, but their bulk, needle fear, and complex operation create adherence gaps. By converting epinephrine into a nasal spray, ARS Pharma taps into a user‑friendly format that aligns with modern consumer expectations for convenience and discretion. This delivery shift not only differentiates neffy from legacy products but also opens new distribution channels, from personal carry‑alls to institutional stockpiles, potentially expanding the addressable market.

Clinical evidence is already validating the concept. A real‑world study cited by Lowenthal reported that about 90% of anaphylaxis episodes were successfully treated with a single neffy dose, mirroring the efficacy of auto‑injectors while eliminating needle‑related hesitation. Moreover, the device’s resilience—withstanding temperatures up to 122 °F and surviving accidental freezing—addresses practical concerns for schools, travel, and outdoor activities. Its 2.5‑year shelf life reduces replacement frequency, lowering long‑term costs for patients and institutions alike. These attributes collectively improve adherence, a critical metric that directly influences outcomes in emergency care.

Looking ahead, neffy’s success may catalyze a wave of needle‑free emergency therapeutics. The Narcan nasal spray’s market impact demonstrated how formulation changes can democratize life‑saving interventions, shifting responsibility from clinicians to laypersons. ARS’s neffyinSchools initiative mirrors this paradigm, ensuring that schools—common sites of first allergic reactions—are equipped with ready‑to‑use, non‑invasive options. As regulators and insurers recognize the value of such innovations, we can expect accelerated approvals and broader reimbursement, prompting other manufacturers to prioritize delivery redesigns across therapeutic areas. The convergence of patient‑centric design, robust efficacy data, and strategic access programs positions neffy as a blueprint for the next generation of emergency medicines.